[Skip to Content]
[Skip to Content Landing]
Comment & Response
March 21, 2019

Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer

Author Affiliations
  • 1Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Center, University of Chicago, Chicago, Illinois
  • 2Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois
JAMA Oncol. 2019;5(5):743. doi:10.1001/jamaoncol.2019.0130

To the Editor Hyperprogressive disease (HPD) has recently been described as an acceleration in tumor growth rate (TGR), with varying numerical definitions, in the context of cancer immunotherapy.1,2 Ferrara et al3 recently analyzed the rate of HPD in patients with non–small cell lung cancer treated with immune checkpoint inhibitors (ICIs) and chemotherapy. We applaud the authors for conducting the first analysis, to our knowledge, of HPD associated with ICIs that includes a comparator arm, but we note a number of concerns.

×